A Phase 1 Study of JNJ-78278343, a T-Cell-Redirecting Agent Targeting Human Kallikrein 2 (KLK2), for Advanced Prostate Cancer

Status

Active, not recruiting

Phases

Phase 1

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-506585-31-00

Acronym

78278343PCR1001

Enrollment

103

Registered

2024-01-11

Start date

2021-07-09

Completion date

Unknown

Last updated

2025-09-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Metastatic castration-resistant prostate cancer

None listed

Sex/Gender

Male

Age

18 Years to No maximum

France, Netherlands, Spain

None listed

Source: EU CTIS · Data processed: Feb 4, 2026